DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI)‘s stock had its “hold” rating reissued by equities researchers at Maxim Group in a research note issued on Monday.

The analysts wrote, “Delmar announced news of another Phase II trial (biomarker driven), N=20-30 in newly diagnosed MGMT-unmethylated glioblastoma multiforme (GBM). The trial will be funded by Guangxi Wuzhou Pharmaceutical Group Co. (private). Management states that data is expected 9-15 months from the time the trial begins.””

DMPI has been the topic of a number of other reports. HC Wainwright reissued a “buy” rating and issued a $12.00 price target on shares of DelMar Pharmaceuticals in a research note on Tuesday, May 30th. Dawson James reissued a “buy” rating on shares of DelMar Pharmaceuticals in a research note on Tuesday, August 8th.

DelMar Pharmaceuticals (DMPI) opened at 1.29 on Monday. DelMar Pharmaceuticals has a 52-week low of $1.13 and a 52-week high of $7.07. The firm has a 50-day moving average of $1.58 and a 200-day moving average of $2.60. The firm’s market cap is $17.36 million.

COPYRIGHT VIOLATION WARNING: “DelMar Pharmaceuticals, Inc. (DMPI) Stock Rating Reaffirmed by Maxim Group” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of international trademark & copyright laws. The original version of this news story can be read at

A hedge fund recently bought a new stake in DelMar Pharmaceuticals stock. Franklin Resources Inc. purchased a new position in DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 1,076,923 shares of the company’s stock, valued at approximately $2,477,000. 13.84% of the stock is currently owned by hedge funds and other institutional investors.

About DelMar Pharmaceuticals

DelMar Pharmaceuticals, Inc is a clinical-stage drug development company. The Company focuses on the treatment of cancer. The Company is engaged in conducting clinical trials in the United States with its product candidate, VAL-083, as a treatment for glioblastoma multiforme (GBM), a form of brain cancer.

Receive News & Stock Ratings for DelMar Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DelMar Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.